Aussie cancer diagnosis firm expands with $3.3b merger
Telix Pharmaceuticals will acquire a German radioisotope manufacturer, giving it greater control of its isotope supply it is using in cancer treatment.
AAP ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Telix Pharmaceuticals
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance
Telix Pharmaceuticals (NASDAQ:TLX) updated on Tuesday its commercial and operational performance for the third quarter of fiscal 2025.
Benzinga ·
Telix Gets Second FDA Rejection For Kidney Cancer Drug
On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix, 89Zr-DFO girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
AAP
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Topics
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
